|
Video: What is a Stock Split?
|
|
Chemomab Therapeutics is a biotechnology company focused on the discovery, development, and commercialization of targeted therapies to treat cancer. Co. is developing small-molecule pan-RAS inhibitors and inhibitors of phosphodiesterase (PDE10) and the ß-catenin pathway. Co.'s pan-RAS program has identified indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation, or pan-RAS inhibition. Co.'s PDE10/ß-catenin program has identified small molecules that inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. According to our Chemomab Therapeutics stock split history records, Chemomab Therapeutics has had 1 split. | |
|
Chemomab Therapeutics (CMMB) has 1 split in our Chemomab Therapeutics stock split history database. The split for CMMB took place on March 17, 2021. This was a 1 for 16 reverse split, meaning for each 16 shares of CMMB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 62.5 share position following the split.
When a company such as Chemomab Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Chemomab Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 62.5 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Chemomab Therapeutics shares, starting with a $10,000 purchase of CMMB, presented on a split-history-adjusted basis factoring in the complete Chemomab Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/13/2019 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$146.40 |
|
End price/share: |
$0.67 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.54% |
|
Average Annual Total Return: |
-64.55% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$45.76 |
|
Years: |
5.19 |
|
|
|
Date |
Ratio |
03/17/2021 | 1 for 16 |
|
|